Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (DE:PX91)
FRANKFURT:PX91
Cassava Sciences (PX91) Stock Price & Analysis
1 Followers
PX91 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€11.50 - €27.80
Previous Close€20.05
Volume130.00
Average Volume (3M)817.00
Market Cap
€862.57M
Enterprise Value€703.91M
Total Cash (Recent Filing)$168.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta-0.65
Next Earnings
Apr 29, 2024EPS Estimate
-€0.43Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,225,211
10 Day Avg. Volume521
30 Day Avg. Volume817
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-17.06
Forecast
1Y Price Target
€93.25Price Target Upside365.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cassava Sciences News
PremiumPress Releases
Redemption Date Announced for Warrants
Bulls Say, Bears Say
Bulls Say
Drug EfficacyCassava’s Cognitive Maintenance Study with simufilam showed that treatment for 18 months stabilized cognition in patients with mild Alzheimer’s disease, a previously unachieved result in AD treatment.
Market PotentialWith low sales uptake of Leqembi in recent quarter, there is a clear market for an effective oral drug with a clean safety profile, positioning simufilam as a strong contender.
Safety And ProgressBlinded MRI data from October 2023 indicated that simufilam is not associated with Amyloid-related Imaging Abnormalities, enhancing its safety profile as a potential long-term treatment option.
Bears Say
Clinical Trial ResultsThe more progressed moderate patients showed larger decline in cognition scores.
Drug EfficacyNew microhemorrhages occurred in 20% of patients treated with simufilam.
Study Design ConcernsThe open label study is non-randomized for most parts, which may affect the strength of the evidence.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.10% Other Institutional Investors
99.90% Public Companies and
Individual Investors
PX91 FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was €11.50 and its highest was €27.80 in the past 12 months.
What is Cassava Sciences’s market cap?
Currently, no data Available
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Apr 29, 2024 which is tomorrow.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Feb 28, 2024. The company reported -€0.471 earnings per share for the quarter, beating the consensus estimate of -€0.49 by €0.019.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Undervalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of €4.95 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -€0.43.
How many shares outstanding does Cassava Sciences have?
Currently, no data Available
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -€0.471 in its last earnings report, beating expectations of -€0.49. Following the earnings report the stock price went up 5.177%.
Which hedge fund is a major shareholder of Cassava Sciences?
Among the largest hedge funds holding Cassava Sciences’s share is Gallacher Capital Management LLC. It holds Cassava Sciences’s shares valued at 13M.
---
Cassava Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€93.25 (365.07% Upside)
€93.25 (365.07% Upside)
Blogger Sentiment
Bullish
DE:PX91 Sentiment 81%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $49.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.85%
12-Months-Change
Fundamentals
Return on Equity
-53.27%
Trailing 12-Months
Asset Growth
-35.42%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
---
PX91 Stock 12 Months Forecast
Average Price Target
€93.25
▲(365.07% Upside)
Technical Analysis
Best Analysts Covering PX91
1 Year
1 Year Success Rate
10/28 ratings generated profit
1 Year Average Return
+36.56%
reiterated a buy rating 16 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +36.56% per trade.
---